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Neuroimage analysis
Application to dementia (and brain lesions)
Motivation
INPUT:
High dimensional data
Multi modal data
Huge amount of data
Prediction
Inference
Diagnosis
Outcome measure
PROCESSING:
Machine learning
Statistics
Automation
Complex patterns
OUTPUT:
Observational research
Interventional research
Clinical practice
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3. Conclusions & future work
Alzheimer’s disease
A global epidemic
Clinical diagnosis (probable AD: acc.: 70%):
- Tests: memory, problem solving, etc.
- Questionnaire: daily activities, behavior, 
personality, etc.
True diagnosis: post-mortem.
Clinical practice: AD defined as a syndrome.
● It gives no clue about its etiology
● Disease modifying therapies must engage 
biological targets.
Need for a AD continuum definition based on 
biomarkers that could potentially lead to 
dementia [1]
[1] Jack, C. R. J., et al. "NIA-AA research framework: towards a biological definition of Alzheimer’s disease." (2017).
Alzheimer’s disease
Biological definition of AD
Using biomarkers for brain state inference. [2]
● A: amyloid biomarker (CSF, PET)
● T: tau pathology biomarker (CSF, PET)
● N: neurodegeneration or neuronal loss 
(CSF, MRI, FDG-PET)
Cognitive staging:
1. Cognitively normal (CN)
2. Mild cognitive impariment (MCI)
3. Dementia 
[2] Jack, Clifford R., et al. "A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers." Neurology 87.5 (2016): 539-547.
Alzheimer’s disease
Preclinical stage of AD
Brain alterations appear ~20 years 
before clinical symptoms appear:
- Better understanding of AD
- Better disease-modifying 
therapies.
Alterations to the A/T/N profile 
might occur before clinical 
and/or cognitive impairment 
occur.
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Casamitjana et al. MRI-based screening of preclinical Alzheimer’s disease for prevention clinical trials Journal 
of Alzheimer’s and Disease (2018)
MRI-based screening
Goal of the study:
● Devise an MRI-based protocol for 
screening preclinical subjects:
○ Non-invasive
○ Cost-efficient
● Provide a proof-of-concept study:
○ Use a public dataset to infere the 
model (ADNI)
○ Apply to private cohorts (HCB)
MRI-based screening
Case study: a proof-of-concept
● Use the publicly available ADNI cohort to build the model
● Use a private cohort to evaluate the model.
MRI-based screening
Results:
❏ ⍴ - prevalence of preclinical subjects among cognitively 
impaired subjects (~20%)
❏ P - precision
❏ R - recall/sensitivity
❏ CPET - cost of a PET scan (~3000€)
❏ CMRI - cost of a MRI scan (~700€)
❏ Cavg - average cost of standard screening (~3700€)
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Puch et al. VNeAT: Voxelwise neuroimage analysis toolbox. NIPS Workshop (2016).
Casamitjana et al. NeAT: Neuroimaging Analysis Toolbox. Application to non-linear modelling of aging and 
atrophy in Alzheimer's Disease. MLMI Workshop (Under review).
NeAT: Neuroimaging Analysis Toolbox
Motivation:
● Standard image analysis softwares include only linear modeling of the brain
Goal: 
● Provide the neuroimaging community with non-linear modelling techniques
● Include statistical inference and model comparison
● Work with data preprocessed using different software:
○ Voxel-based morphometry VBM (e.g: SPM)
○ Surface-based morphometry SBM (e.g: FreeSurfer)
NeAT: Neuroimaging Analysis Toolbox
Toolbox:
● Modular
● Low-memory constraints: batch processing
● Cost-efficient: parallelization of the most 
demanding tasks.  
Usage:
● Command-line interface
● Config file (*.yaml)
● Data loader:
○ Images: *.nii, *.nii.gz, *.thickness
○ Variables: *.csv, *.xls
NeAT: Neuroimaging Analysis Toolbox
Modelling methods:
● GLM: General Linear Model
● PolyGLM: GLM with polynomial basis 
expansion.
● GAM: Generalized Additive Model
● PolySVR: SVR with polynomial kernel
● Gaussian SVR: SVR with Gaussian 
kernel.
Statistical inference:
● F-test
● MSE and R2 coefficient
● AIC: Aikaike information criteria
● PRSS and VNPRSS: 
(Variance-normalized) Penalized 
Residual Sum of Squares.
Model comparison (L statistical maps):
● ABSdiff / SE maps (L=2)
● Best-fit map (L>1)
● RGB map (L=3)
NeAT: Neuroimaging Analysis Toolbox
Validation results: Atrophy patterns across AD continuum.
Left Hippocampus Right Precuneus
PolyGLM (magenta), GAM with B-splines (cyan), PolySVR (yellow), GaussianSVR (red) 
using the ‘Best-fit’ map
NeAT: Neuroimaging Analysis Toolbox
Validation results: Effects of apoE4 in brain aging.
Right Hippocampus Right Caudate
Non-carriers NC (red), heterozygotes HE (green), homozygotes HO (blue)
HO - 2 copies of ε4 allele
HE - 1 copies of ε4 allele
NC - 0 copies of ε4 allele
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Casamitjana et al. Projection to Latent Spaces Disentangles Specific Cerebral Morphometric Patterns 
Associated to Aging and Preclinical AD. Abstract accepted in AAIC (2018)
Casamitjana et al. Relationship between CSF biomarkers and structural brain information in the 
asymptomatic phase of AD. To be submitted.
Latent processes for brain morphology
Goal:
● Disentangle brain aging and brain dementia pattern
Methodology:
● Projection to Latent Structures (PLS)
● Two orthogonal models:
○ Brain aging
○ Brain dementia
Latent processes for brain morphology
Dataset:
T0:= AB ⋲ [230, 295]: N=104, Age=71.47 ± 6.07
T1:= AB ⋲ [175, 230): N=109, Age=71.49 ± 5.52
T2:= AB ⋲ [88,175): N=108, Age=75.03 ± 6.36
Model:
(A) PLS - aging
X ~ age + gender → w_1
Y ~ imaging features (ALL). 
(B) PLS - dementia
X ~ biomarkers: AB, PTAU, TTAU
Y_o ~ imaging features orthogonal to age, 
computed from PLS-aging
Y_o = Y - w_1·w_1^T·Y = (I - w_1·w_1^T )·Y
       A single PLS for each ROI (independent).
Latent processes for brain morphology
Relevant regions:
- Temporal lobe: T0,1,2
- Amygdala
- Inferior temporal
- Enthorhinal cortex
- Parietal lobe: T1,2
- Postcentral
- Precentral
- Paracentral
- Frontal cortex: T0
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Petrone et al. Characteristic Brain Volumetric Changes in the AD Preclinical Signature. Abstract accepted in 
AAIC Conference (2018)
Petrone et al. Characteristic Brain Volumetric Changes in the AD Preclinical Signature. To be submitted.
Longitudinal studies
Definition: 
● For each subject si under the study, several visits Li ∋ [li1, li2, …, liLi]are 
collected. At each visit CSF, MRI and cognitive profile (CP) are collected.
● For each lij with j>1 quantitative difference is computed for: 
○ dCSFi1 = CSFi2 - CSFi1 →   called biomarkers 
○ dMRIi1 = MRIi2 - MRIi1 →   called Jacobian features
Goal:
● Show that a preclinical signature is found in jacobian features and they can be 
used for image classification.
Longitudinal studies
Labels are defined using reference/target Aᶔ. Analysis is performed at the image level, not in the 
subject level.
1. A-/A- (Neg)   
2. A-/A+ (Conv)    
3. A+/A+ without symptoms (Pos)        
4. A+(NC)/A+(MCI,AD) (PostMCIAD) 
5. A+/A+ with symptoms (Possymp)    
Method:
- Correlation between dCSF-A and dMRI
- Statistical maps with relevant correlations 
through hypotesis testing. 
Longitudinal studies
Neg
Pos
PostMCIAD 
Result 1. Relationship between 
CSF-MRI.
- Changes in CSF might describe 
changes in brain morphology in 
preclinical stages but not in 
dementia stages
Longitudinal studies
Result 2. Relationship between 
CSF-MRI.
- There are some regions that 
experience atrophy but 
others experience 
neuro-compensation.
Longitudinal studies
Result 3. Group comparison with 
controls.
- There are some regions that 
experience atrophy but 
others experience 
neuro-compensation.
      Preclinical signature Dementia signature
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Conclusions
- Dementia = syndrome; disease = biological continuum.
- Preclinical stage of AD is key to:
- Better understanding of the etiology of the disease
- Design better interventional/therapeutic plan.
- Large scale studies involving Pre-AD subjects might create huge impact on 
research:
- Need for cost-effective clinical screening protocols (MRI-based, blood-based).
- Brain morphology follow non-linear patterns along the AD continuum.
- apoE4 is a risk factor for developing AD.
Future directions
- Observational research:
- Develop and apply multimodal modelling strategies: design multimodal algorithms that help 
understanding AD biology and describe brain changes. MRI + fMRI + DWI
- Disease progression modelling: use longitudinal data to model the progression along the AD 
continuum
- Differential diagnosis: specific patterns for different type of dementia: AD, LBD, FTD
- Translational research: from the lab to clinic.
- Personalized medicine: outlier detection for subject specific diagnosis of AD
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Outline
- Motivació: neuroimatge, tipus d’imatge, machine learning, predictive vs inference.
- Esquema de la xerrada
- Alzheimer: què és? Definició biològica. Menció a altres demències que poden compartir característiques. 
Tipus d’estudis: observational and interventional research.
- Objectiu: detectar els canvis biològics abans que els clínics
- App 1: necessitem construir bases de dades tant per estudi com per prevenció. Les millors tècniques 
són cares i invasives. Solucions: machine learning MRI (esmentar blood)
- App 2: nonlinear patterns of atrophy + apoe4 gene.
- App 3: latent processes governing brain morphology related to CSF biomarkers. Volume compensation 
in the preclinical stages of AD.
- App 4: Longitudinal jacobian features: improve classification performance + indicate structural 
changes.
- Future work: 
- Need for large study cohorts (efforts put in UK biobank, ADNI or Alpha).
- Translational research.
-
